Navigation Links
Alnylam Announces Advancement of a New RNAi Therapeutic Development,Program for the Treatment of Liver Cancer

a rodent model;

-- Silencing of KSP mRNA in vivo by greater than 50 percent after a single injection of a KSP-specific siRNA in a rodent model; and

-- Halting of human cancer cell proliferation in vitro when KSP was silenced by a target-specific siRNA.

Alnylam's RNAi therapeutic, ALN-VSP01, is comprised of two small interfering RNAs, or siRNAs, the molecules that mediate RNAi. Each siRNA targets a distinct and well-validated gene in the growth and proliferation of tumors: VEGF, a key mediator of tumor angiogenesis; and KSP, a protein required for cell division that, when inhibited, leads to cell arrest and cell death in dividing cells. ALN-VSP01 is formulated using Alnylam's novel liposomal formulation technology, which has been used to achieve delivery of siRNAs to cells of the liver and efficient silencing of genes expressed in that organ. Liposomal delivery can also be optimized for delivery to other organs and tumor types, such that ALN-VSP01 may ultimately have potential for a range of solid tumors. Alnylam's collaborator, Inex Pharmaceuticals Corporation, is manufacturing the lipid-based formulation as the company prepares for pre-IND toxicology studies with ALN-VSP01.

"Despite many advances in the treatment of cancer with targeted small molecules and antibody therapeutics, the clinical impact of these therapies is generally measured in only months of survival benefit. New modalities like RNAi therapeutics offer the potential to advance cancer therapy to a whole new level," said George D. Demetri, M.D., of Dana-Farber Cancer Institute and Harvard Medical School. "I'm encouraged by Alnylam's pre-clinical data demonstrating the ability to silence disease pathway genes with delivery of RNAi therapeutics, and believe that the application of this approach for the treatment of primary and secondary liver cancers holds considerable promise."

About Liver Cancer

Primary liver cancer is cancer that forms in the tissues of the l
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Alnylam Reports Results of Human Experimental Infection Model with Respiratory Syncytial Virus
2. Alnylam and Stanford University Scientists Discover New Role for microRNAs (miRNAs) in T Cell Biology and Immunity
3. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
4. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
6. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
7. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
8. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
9. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
10. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
11. Protox Announces Positive Clinical Data from Prostate Cancer Study

Post Your Comments:
(Date:11/25/2009)...v. 25 Praxis Electronic Medical Re...n Academy of Family Physicians, (AAFP) Family Prac...urvey for improving medical quality, health mainte...w ARRA Stimulus legislation. Praxis also ranked #1... effect in determining their salary. Finally, Prax...
(Date:11/25/2009)... Pharmasset, Inc. (Nasda...y committed to discovering, developing and commerc...ported financial results for the fiscal year ended...set held $58.4 million in cash, cash equivalents a... and 2009 Highlights ,, RG7128 ,, Phase...
(Date:11/25/2009)... The FDA granted traditional appro...n-nucleoside reverse transcriptase inhibitor (NNRT...ated for use in treatment-experienced adults who a...ns resistant to an NNRTI and other antiretroviral ...n 48-week data from two Phase 3 studies known as D...
Breaking Medicine Technology:Praxis EMR Wins Top Rankings in 2009 AAFP EHR User Satisfaction Survey 2Pharmasset Reports Fiscal Year End 2009 Financial Results 2Pharmasset Reports Fiscal Year End 2009 Financial Results 3Pharmasset Reports Fiscal Year End 2009 Financial Results 4Pharmasset Reports Fiscal Year End 2009 Financial Results 5Pharmasset Reports Fiscal Year End 2009 Financial Results 6Pharmasset Reports Fiscal Year End 2009 Financial Results 7Pharmasset Reports Fiscal Year End 2009 Financial Results 8Pharmasset Reports Fiscal Year End 2009 Financial Results 9Pharmasset Reports Fiscal Year End 2009 Financial Results 10U.S. Food And Drug Administration (FDA) Grants Traditional Approval for INTELENCE(R) (etravirine) 2U.S. Food And Drug Administration (FDA) Grants Traditional Approval for INTELENCE(R) (etravirine) 3U.S. Food And Drug Administration (FDA) Grants Traditional Approval for INTELENCE(R) (etravirine) 4U.S. Food And Drug Administration (FDA) Grants Traditional Approval for INTELENCE(R) (etravirine) 5Measuring intellectual disability 8977 1Measuring intellectual disability 8977 2M2SYS Technology to Offer Desktop Biometric Technology to Kronos Customers 8975 1M2SYS Technology to Offer Desktop Biometric Technology to Kronos Customers 8975 2BD Announces CE Marking of BD ProbeTec 26amp 3B 238482 3B Qx Amplified Assays to Improve Detection of Chlamydia trachomatis and Neisseria gonorrhoeae 49844 1BD Announces CE Marking of BD ProbeTec 26amp 3B 238482 3B Qx Amplified Assays to Improve Detection of Chlamydia trachomatis and Neisseria gonorrhoeae 49844 2BD Announces CE Marking of BD ProbeTec 26amp 3B 238482 3B Qx Amplified Assays to Improve Detection of Chlamydia trachomatis and Neisseria gonorrhoeae 49844 3BD Announces CE Marking of BD ProbeTec 26amp 3B 238482 3B Qx Amplified Assays to Improve Detection of Chlamydia trachomatis and Neisseria gonorrhoeae 49844 4
...IEW, Calif., June 22, 2007 /PRNewswire/ -- MAP,Pha...esent Phase 2,data from its Unit Dose Budesonide (...the World Asthma Meeting at the Lutfi Kirdar,Conve... The oral and poster presentation entitled, "Effic...lation of budesonide for,nebulized delivery in a 6...
... Announces Bioinformatics Partnership with,Illumin...une 21, 2007,-GenoLogics, a leading developer of l... sciences research, today announced that,it has pe...technology partner and participant in IlluminaConn... by Illumina to advance,data integration and analy...
Other Medicine Technology:MAP Pharmaceuticals to Present Unit Dose Budesonide Phase 2,Clinical Data at the World Asthma Meeting 2GenoLogics Announces Bioinformatics Partnership with Illumina 2GenoLogics Announces Bioinformatics Partnership with Illumina 3
(Date:11/29/2009)...tors unaware the sleep disorder boosts urine produ...(HealthDay News) -- People who wake up during the ...rological problem. Sleep apnea, a breathing-relate...tudy suggests that nighttime urination, or nocturi...bstructive sleep apnea, a disorder in which soft t...
(Date:11/28/2009)...ffenders were more likely to consider change after..., , FRIDAY, Nov. 27 (HealthDay News) -- ...nsider why they should stop their dangerous behavi...s, researchers have found. , The new study incl...ile-impaired convictions, who were randomly assign...
(Date:11/27/2009)... Biotech firm Replikins Ltd. toda...N1 virus genomic data. It shows that the lethalit....d. 4.5) during the virus,s current outbreak in th...is week of 2.0 (s.d. 0.1). The H1N1 infectivity co... Boston (PRWEB) November 27, 2009 -- Biot...
(Date:11/27/2009)..., KIBBUTZ SHAMIR, Israel, Nov. 27 /PRNewswire-Fir...SHMR ) ( "Shamir" ), a leading provider of innovat... market, announced today that its board of directo...egate amount of US$ 10 million (approximately NIS ...sentative rate of exchange), or approximately US$ ...
(Date:11/27/2009)... Voyant Health™ announced t... has licensed its TraumaCad Enterprise orthopedic ...low solution. , (PRWEB) N... today that Spectrum Health (Grand Rapids, Michiga...c templating solution and its TraumaCad Extend wor...
Breaking Medicine News(10 mins):Health News:Sleep Apnea May Cause Nighttime Urination 2Health News:Sleep Apnea May Cause Nighttime Urination 3Health News:Drunk Drivers May Respond to Brief Motivational Interview 2Health News:Lethality of H1N1 Virus Drops to "Non-Epidemic Resting Levels" in Current Cycle; Virus' Infectivity Remains Increased 2Health News:Lethality of H1N1 Virus Drops to "Non-Epidemic Resting Levels" in Current Cycle; Virus' Infectivity Remains Increased 3Health News:Lethality of H1N1 Virus Drops to "Non-Epidemic Resting Levels" in Current Cycle; Virus' Infectivity Remains Increased 4Health News:Lethality of H1N1 Virus Drops to "Non-Epidemic Resting Levels" in Current Cycle; Virus' Infectivity Remains Increased 5Health News:Shamir Optical Industry Ltd. Announces Declaration of a Cash Dividend 2Health News:Shamir Optical Industry Ltd. Announces Declaration of a Cash Dividend 3Health News:Voyant Health Announces: Spectrum Health Licenses TraumaCad Enterprise and TraumaCad Extend 2Health News:Voyant Health Announces: Spectrum Health Licenses TraumaCad Enterprise and TraumaCad Extend 3
... Privatizing water supplies is only a pretext for ...precious resources of the people at large, activis...orldwide in the bottled water market, corporations...ontrols one-third of the U.S. market and sells 70 ...
... A revolutionary new imaging technology is expecte...s. Elasticity imaging is an ultrasound technique r... measure the stiffness of tissue, relative to surr...psies turn up positive for cancer. In a re...
... Loading a Super Soaker (a brand of recreational ...ight, worse ejaculating on stuffed animals, how de... are heard these days after a popular 17-year-old .... A week or so later, Mayor Tish Colombi and ...
... New tuberculosis (TB) vaccines in development hav...strains of TB, including multidrug-resistant (MDR)...rald C. Sadoff, president and CEO of the Aeras Glo... solely to creating new TB vaccines, is working to...
... Additional beneficial effects on cardiometabolic ...s in trials of the anti-obesity drug rimonabant ma...e in the June issue of Drug and Therapeutics Bulle...n cardiometabolic risk factors are beyond those ex...
... Tobacco is perhaps the most common addiction all .... Alarmed by the devastating impact of tob...ld Health Organization is calling for stringent re...1 crore, according to WHO estimates. The ...
Other Medicine News:Health News:Multinationals Exploit Groundwater Sources, and People Suffer 2Health News:Multinationals Exploit Groundwater Sources, and People Suffer 3Health News:Multinationals Exploit Groundwater Sources, and People Suffer 4Health News:Multinationals Exploit Groundwater Sources, and People Suffer 5Health News:Beer Bashes of Teens Spinning Out of Control in US 2Health News:New TB Vaccines in Could Protect Against All Drug Resistant Strains 2Health News:New TB Vaccines in Could Protect Against All Drug Resistant Strains 3Health News:Anti-obesity Drugs Claimed Additional Benefits on cardiometabolic Risk Factors Questioned 2Health News:Tobacco Menace and What can Be Done About It 2Health News:Tobacco Menace and What can Be Done About It 3Health News:Tobacco Menace and What can Be Done About It 4
Shahinian Lacrimal Cannula
Solo-Care Multipurpose Solution
Graether Collar Button On Handle
Graether Irrigating Collar Button
Medicine Products: